Probe Reports from the NIH Molecular Libraries Program (2013-06-14)
Sarah A. Scott, Matthew C. O’Reilly, J. Scott Daniels, Ryan Morrison, Roger Ptak, Eric S. Dawson, Nichole Tower, Julie L. Engers, Darren W. Engers, Thomas Oguin, Paul Thomas, Lucille White, H. Alex Brown, Craig W. Lindsley
PMID23762931
ABSTRACT
A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML298 (CID 53393915), a potent, >53-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC
MATERIALS